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The tumorigenesis of small intestinal neuroendocrine tumors (SI-NETs) is poorly under-
stood. Recent studies have associated alternative polyadenylation (APA) with proliferation,
cell transformation, and cancer. Polyadenylation is the process in which the pre-messenger
RNA is cleaved at a polyA site and a polyA tail is added. Genes with two or more polyA
sites can undergo APA. This produces two or more distinct mRNA isoforms with different
3′ untranslated regions. Additionally, APA can also produce mRNAs containing different
3′-terminal coding regions. Therefore, APA alters both the repertoire and the expression
level of proteins. Here, we used high-throughput sequencing data to map polyA sites and
characterize polyadenylation genome-wide in three SI-NETs and a reference sample. In the
tumors, 16 genes showed significant changes of APA pattern, which lead to either the 3′
truncation of mRNA coding regions or 3′ untranslated regions. Among these, 11 genes had
been previously associated with cancer, with 4 genes being known tumor suppressors:
DCC, PDZD2, MAGI1, and DACT2. We validated the APA in three out of three cases with
quantitative real-time-PCR. Our findings suggest that changes of APA pattern in these 16
genes could be involved in the tumorigenesis of SI-NETs. Furthermore, they also point to
APA as a new target for both diagnostic and treatment of SI-NETs. The identified genes
with APA specific to the SI-NETs could be further tested as diagnostic markers and drug
targets for disease prevention and treatment.
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INTRODUCTION
Small intestinal neuroendocrine tumors (SI-NETs) are a homoge-
neous group of tumors originating primarily from the serotonin
producing enterochromaffin neuroendocrine cells dispersed as
solitary cells between the mucosal cells in the small intestine (1).
Most SI-NETs tend to be slow growing with a low Ki-67 prolif-
eration index (2). The primary tumor, regional node metastases,
and related mesenteric fibrosis may give rise to local symptoms as
bowel obstruction and/or vascular encasement. The presence of
liver metastases may give rise to the carcinoid syndrome including
diarrhea, facial flushing, and on sight cardiac and pulmonary dis-
ease, caused by release of serotonin and vasoactive peptides from
the liver metastases (2).
Both the incidence and prevalence of SI-NETs have been
increasing during the last three decades (3). Nowadays, SI-NETs
are the second most prevalent gastrointestinal cancer after colonic
cancer (4). Radical surgical intervention is the only curative treat-
ment. However, SI-NETs are difficult to diagnose, as the symptoms
often are unspecific. Therefore, many patients are first diagnosed
once metastases have occurred and curative surgery is no longer
an option (1).
Polyadenylation is a co-transcriptional process that consists of
cleavage of the pre-messenger RNA (pre-mRNA) at a polyA site
and addition of a polyA tail to the 5′ cleavage product. This process
is necessary for normal mRNA 3′-end formation, transcription
termination, and mRNA export from the nucleus (5, 6). Studies
have shown that almost all eukaryotic pre-mRNAs and several
non-coding transcripts have polyA sites and are polyadenylated.
More than two-thirds of human genes have multiple polyA sites
and can therefore undergo alternative polyadenylation (APA) (7).
This produces two or more distinct mRNA isoforms with differ-
ent 3′ untranslated regions (3′ UTRs). In some cases, APA also
produces mRNAs containing different 3′-terminal coding regions.
Therefore, APA alters both the repertoire and the expression level
of proteins (Figure 1).
Alterations in polyadenylation can cause various diseases (8,
9) and several studies have linked cellular proliferation, transfor-
mation, and cancer progression to APA. Proliferation correlates
with enhanced proximal polyA site usage leading to expression
of mRNAs with 3′ truncated coding regions (10) and truncated
3′ UTRs (5, 10). Cell transformation is associated with 3′ UTR
truncation (11–14) and changed APA pattern (10, 15), where
transformed cells express mRNAs with shorter 3′ UTRs compared
to non-transformed cells with similar proliferation rate (12). Fur-
thermore, 3′ UTR shortening is linked to poor cancer prognosis
(16). The APA pattern also differs according to cancer subtype
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FIGURE 1 |Types of APA. UTR-APA: APA utilizing polyA sites located in
the 3′ UTR of the last exon is called UTR-APA and results in mRNAs with
the same coding region, but with different 3′ UTR length. CR-APA: APA
utilizing polyA sites located in introns, or in the coding region of exons, is
called CR-APA and results in mRNAs with 3′ truncated coding regions.
Adapted from Ref. (53)
(11), suggesting that the APA pattern could be used as a biomarker
for cancer classification.
Considering the previous evidence, we hypothesized that APA
leading to 3′ truncation of mRNAs could participate in the tumori-
genesis of SI-NETs. To investigate this hypothesis we used high-
throughput sequencing data to map polyA sites and characterize
APA in SI-NETs genome-wide. We compared polyA site usage in a
SI-NET group of three samples, with polyA site usage in a normal
neuroendocrine reference sample, pituitary (PIT), and discovered
16 genes with significant APA specific to the SI-NETs, which lead
to either 3′ truncation of mRNA coding regions or 3′ UTRs.
MATERIALS AND METHODS
HUMAN CLINICAL SAMPLES AND RNA ISOLATION
Surgical specimens from SI-NETs were obtained from three
patients undergoing surgery at the Department of Surgical Gas-
troenterology, Rigshospitalet (Table 1). The study was approved
by the regional scientific ethical committee (journal number 01
313726). Signed, informed consent was obtained from the patients.
Immediately after tumor resection, tumor tissue samples from
the surgical specimens were placed in RNAlater® (Applied Biosys-
tems, Carlsbad, CA, USA) for overnight incubation. Samples were
subsequently stored at −80°C until RNA was extracted using
TRIzol (Life Technologies,Carlsbad,CA,USA). The reference sam-
ple (PIT), human pituitary RNA, was purchased from BioChain
(Hayward, CA, USA).
SEQUENCING
Total RNA from the three SI-NETs and the reference sample (PIT)
were sequenced with single-molecule direct RNA-sequencing
(DRS) at Helicos BioSciences (Boston, MA, USA) (17). The 3′
blocking reaction was performed with 3′ deoxyATP (Jena Bio-
sciences, Germany) by incubating the reaction mixture at 37°C for
30 min.
READ PROCESSING AND MAPPING
Raw DRS reads starting with one or more Ts were trimmed as these
can be due to inefficient locking of the RNA with the polyT primer
at the beginning of the sequencing (17). Trimmed reads were
mapped to the genome (hg19) with HeliSphere software (http:
//sourceforge.net/projects/openhelisphere/) using a seed length of
18 nt and allowing only one mismatch in the seed region. Only
uniquely mapped reads with a minimum length of 21 nt and a
minimum score of 4 where further analyzed. We additionally dis-
carded all reads that may arise from internal priming events. DRS
reads are sequenced by synthesis, and thus, they are reverse com-
plementary to the original RNA fragments (17). We checked the
10-nt immediately downstream of the read end in the comple-
mentary strand for adenines. In the case that the first six or more
of these nucleotides were adenines the read was discarded (14). A
summary of the data after the different steps can be seen in Table 2.
IDENTIFICATION OF polyA SITES
It is known that the cleavage process is inefficient and can vary
within a few nucleotides (18). To account for this variability, we
cluster iteratively the 5′ end of mapped reads that were <24 nt
apart (14, 18). For each of these clusters, the cleavage site is defined
as the median position of the cleavage sites in the cluster (Figure 2).
As previous works have shown that APA is very common and that
even very infrequently used polyA sites are real (7), we kept all
polyA sites that have at least one read in at least two samples,
or that have two or more reads. Next, each of the clusters was
annotated according to the location of the cleavage site using the
genome annotation from Ensembl66 (19). PolyA sites were classi-
fied as 5′ UTR, CODING, or 3′ UTR if overlapping these regions
of coding genes; ncGENE if overlapping a non-coding gene; PRO-
MOTER if they were located in the 1000 bases upstream of a gene;
DOWNSTREAM if they were located in the 1000 bases down-
stream of a gene; and INTERGENIC otherwise (Figure 3A). PolyA
sites found in both introns and exons of the coding region are clas-
sified as CODING, as usage of these changes the coding region of
the mRNA. As DOWNSTREAM polyA sites (≤1 kB) have many
more reads than other intergenic polyA sites (Figure 3B), we asso-
ciated the polyA sites in this proximal intergenic region (≤1 kB)
to the upstream gene and included them in the analysis of APA.
IDENTIFICATION OF APA IN SI-NETs
We restricted the analysis to protein coding genes. For each gene,
we selected only those polyA sites that have at least 10% of all reads
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Table 1 | SI-NET biopsies.
Identifier Tissue of origin Sex/age Synaptophysin Chromogranin Serotonin CD117
NE MTT Ileum M/73 + + + −
NE CT1 Ileum F/66 + + NA NA
NE 2TC Ileum M/73 + + + −
Table 2 | Read processing statistics.
NE MTT NE CT1 NE 2TC PIT
Raw reads 4895411 10878794 8859412 9773879
Uniquely mapped reads
(>21 nt)
2012076 4465454 3675490 4027944
Reads filtered after
removing internal
priming events
1918905 4266418 3499253 3816258
Clusters (including
singletons)
686450 1352151 1296130 1289606
PolyA sites 221147 398528 379890 385451
FIGURE 2 | Schematic representation of read processing and
clustering.
mapped to a gene in a given sample. By doing this, we excluded
from the analysis those polyA sites that could have little or no
impact on the expression levels or the regulation of the mRNA.
For each gene we created a contingency table with the counts of
reads for each polyA site, where in each column we had represented
a polyA site identified in one or more samples and on each row we
had each of the samples. To identify differential polyadenylation
we performed fisher exact tests with R (R Development Core Team
2008) for each pair of samples. After multiple test correction, only
those cases in which no statistical difference was found between
the samples in the SI-NET group [false discovery rate (FDR)>0.1]
and significant differences were found for all the samples in the SI-
NET group compared to the reference sample (PIT) (FDR <0.1)
were considered significant.
MANUAL SELECTION OF APA CASES
Firstly, we selected the genuine cases of APA, by manually remov-
ing genes if: (1) there is no APA within the gene alone, but only
in tandem transcripts containing the gene (11 genes removed).
(2) APA is caused by an overlapping gene (one gene removed).
Secondly, we selected the cases of APA leading to a reasonable
expression in the SI-NETs, by manually removing genes if: (3) the
implicated polyA sites have <10 reads in 2/3 of the SI-NETs (11
genes removed). Lastly, we selected the cases of APA, which lead to
3′ truncation of the mRNA, by manually removing genes if: (4) the
most distal polyA site of the gene is primarily used in the SI-NET
group (14 genes removed). (5) The most proximal of the polyA
sites is primarily used in the reference sample (PIT) (eight genes
removed). The manually removed genes are listed in Table S2 in
Supplementary Material.
QUANTITATIVE REAL-TIME-PCR VALIDATION
cDNA was synthesized from the RNA samples using High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA) according to the manufactures instructions. Quan-
titative real-time-PCR (Q-RT-PCR) was performed with SYBR®
GreenER™ qPCR SuperMix for ABI PRISM® (Life Technologies,
Carlsbad, CA, USA) on the ABI PRISM® Instrument (Applied
Biosystems, Foster City, CA, USA). Primer sequences were as
follows:
• DCC, upstream of proximal polyA site:
DCC-INT5-FW: 5 ′-acccgtcaccttcttttcct-3′
DCC-INT5-RV: 5 ′-caccgtgccctattttgtct-3′
• DCC, upstream of distal polyA site:
DCC-INT13-FW: 5 ′-aaaaacgcagtacggcaact-3′
DCC-INT13-RV: 5 ′-tgggatgggttctttctcag-3′
• PDZD2, upstream of proximal polyA site:
PDZD2-INT3-FW: 5 ′-gtgagaccctgtccctacca-3′
PDZD2-INT3-RV: 5 ′-gtaaagcaaccatgccacct-3′
• PDZD2, upstream of distal polyA site:
PDZD2-EX26-FW: 5 ′-gtcggcctagagaggtcctt-3′
PDZD2-EX26-RV: 5 ′-catgcaccttgcactgactt-3′
• LRRFIP1, upstream of proximal polyA site:
LRRFIP1-INT39-FW: 5 ′-gtcctgcagaaccaaagagc-3′
LRRFIP1-INT39-RV: 5 ′-aagctttcctgacggtctga-3′
• LRRFIP1, upstream of distal polyA site:
LRRFIP1-EX76-FW: 5 ′-cgctggaagtgatgatcaaa-3′
LRRFIP1-EX76-RV: 5 ′-gcttggtaatggcttgtggt-3′
RESULTS
GLOBAL CHARACTERIZATION OF polyA SITE USAGE REVEALS
SIMILARITY BETWEEN SI-NETs
Our first objective was to map polyA sites in SI-NETs genome-
wide and characterize APA. To perform this characterization, total
RNA from three SI-NET samples (NE MTT, NE CT1, and NE
2TC) and from a reference sample (PIT) were sequenced using
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FIGURE 3 | (A) Distribution of identified polyA sites across the genome for each of the samples analyzed. (B) Average number of reads per polyA site in
different genomic regions.
DRS (17). DRS is a well established method, which have been
used in several other studies to map polyA sites genome-wide (14,
17, 20, 21). The SI-NETs originate from neuroendocrine cells of
the small intestine, which are solitary interspersed cells (22). It
is very difficult to identify and collect enough normal neuroen-
docrine cells as a control sample, and scrapings of the mucosa
adjacent to the tumors are thus normally used as reference sam-
ples (23). However, we chose to use pituitary as reference sample as
we expected that the neuroendocrine cells of the pituitary are phe-
notypically closer to the neuroendocrine cells of the small intestine
than the mixture of different cell types from the mucosal scrap-
ings. From the DRS we obtained a total of 4895411 (NE MTT),
10878794 (NE CT1), and 8859412 (NE 2TC) reads. The final fil-
tered reads were mapped to 221147 (NE MTT), 398528 (NE CT1),
and 379890 (NE 2TC) polyA sites. These sites mapped to vari-
ous genomic regions in the samples (Figure 3). Fisher exact tests
found 11031 polyA sites, located in 97% of the expressed protein
coding genes, with no statistical difference in usage between the
individual SI-NETs (FDR>0.1). This shows similarity between the
three SI-NET samples. The sequencing data obtained by DRS have
been deposited to the National Center for Biotechnology Informa-
tion (NCBI)’s Gene Expression Omnibus (GEO), with accession
number: GSE56657.
ALTERNATIVE USAGE OF polyA SITES IN THE SI-NETs
The second aim of the project was to identify protein coding genes
in SI-NETs with a differential APA pattern compared to the refer-
ence sample. Using fisher exact tests we identified 61 genes with
statistically significant APA between the SI-NET group and the
reference sample (Table S1 in Supplementary Material). From
these 61 genes, 45 genes were removed manually, to select only
the genuine cases of APA, which lead to either 3′ truncation of
mRNA coding regions or 3′ UTRs (Table S2 in Supplementary
Material). The 16 selected genes with APA specific to the SI-NETs
are described below, including a description of the possible impli-
cations for protein isoform and expression (Table S3 and Figure
S1 in Supplementary Material). Interestingly, 11 out of these 16
genes have previously been associated with cancer, with 4 of the
genes being known tumor suppressors. These 16 genes with APA
specific to the SI-NETs could be tested as diagnostic markers and
drug targets for disease prevention and treatment.
GENES WITH UTR-APA SPECIFIC TO THE SI-NETs
Of the 16 genes with APA specific to the SI-NETs, 9 genes had
significant UTR-APA leading to 3′ UTR shortening in a larger pro-
portion of mRNAs than in the reference sample. These genes are:
PSMD8,DACT2,TM9SF3,CD59,ANKH,CIAO1,SRSF5,MRSP16,
and NDUFA6. The shortening of 3′ UTRs plays an important part
in post-transcriptional regulation, as the 3′ UTR contains target
sites for microRNAs (miRNAs), which control mRNA turnover
and translation rate (24). Because of miRNA target site loss,
mRNAs with shorter 3′ UTRs are more stable and produce more
protein (5, 11, 12). We mapped the target sites of all human miR-
NAs to the 3′ UTRs of genes displaying UTR-APA (Figure S2 in
Supplementary Material). The miRNA target site predictions were
downloaded from microRNA.org (25). Only conserved miRNAs
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with a good score were mapped. We then compared the miRNA
target sites in the 3′ UTRs of the nine genes to miRNA-profiles of
five primary SI-NET samples from another study (26). We con-
sidered only the miRNAs that were detected in a minimum of
four out of these five primary SI-NET samples. For all nine genes,
exceptDACT2, the 3′UTR shortening leads to loss of miRNA target
sites for miRNAs detected in SI-NETs, suggesting an upregulated
expression for these genes. See Table 3 for a detailed description
of the genes with UTR-APA.
GENES WITH CR-APA SPECIFIC TO THE SI-NETs
Seven of the genes identified had significant CR-APA leading to 3′
truncated coding regions in a larger proportion of mRNAs than
in the reference sample. These genes are: DCC, PDZD2, MAGI1,
ZCWPW2, LRRFIP1,RIC3, andTHADA. CR-APA does not lead to
nonsense-mediated decay and the expressed mRNAs thus trans-
late into C-terminally truncated protein isoforms that could be
non-functional or have functions different from the full-length
protein (33). The seven genes with CR-APA are described in detail
in Table 4.
Q-RT-PCR VALIDATION OF APA
Three genes were selected for Q-RT-PCR validation:DCC,PDZD2,
and LRRFIP1. cDNA was synthesized from total RNA from all four
samples. Primers were designed as sets targeting the regions just
upstream of a proximal and a distal polyA site with significant
Table 3 | Genes with UTR-APA specific to the SI-NETs.
Gene Function Role in cancer APA Functional consequence
PSMD8 Subunit of the
proteasome
Overexpressed in
breast cancer (27)
Increased usage of a
proximal polyA site
in the 3′ UTR
Shortening of 3′ UTR by 325 nt with loss of miRNA target sites for
three miRNAs present in SI-NETs: hsa-mir-22*, hsa-mir-192*, and
hsa-mir-1263
DACT2 Negative regulator of
the TGF-β/nodal
signaling pathway
Tumor suppressor
(28)
Increased usage of
two proximal polyA
sites in the 3′ UTR
Shortening of 3′ UTR by up to 12113 nt without loss of miRNA
target sites
TM9SF3 Transmembrane
protein with
unknown function
Unknown Increased usage of
two proximal polyA
sites in the 3′ UTR
Shortening of 3′ UTR by up to 2848 nt with loss of miRNA target
sites for 13 miRNAs present in SI-NETs: hsa-mir-1826,
hsa-mir-338-5p, hsa-mir-552, hsa-mir-532-3p, hsa-mir-7-2*,
hsa-mir-7-1*, hsa-mir-10b*, hsa-mir-140-3p, hsa-mir-193b*,
hsa-mir-550*, hsa-mir-200c*, hsa-mir-17*, and hsa-mir-93*
CD59 Membrane
complement
regulatory protein
Overexpressed and
anti-apoptotic (29)
Increased usage of
two proximal polyA
sites in the 3′ UTR
Shortening of 3′ UTR by up to 4707 nt with loss of miRNA target
sites for one miRNA present in SI-NETs: hsa-mir-629
ANKH Pyrophosphate
transport regulator
Amplified and
suggested
overexpressed (30)
Increased usage of a
proximal polyA site
in the 3′ UTR
Shortening of 3′ UTR by 4879 nt with loss of miRNA target sites
for eight miRNAs present in SI-NETs: hsa-mir-330-3p,
hsa-mir-29b-2*, hsa-mir-1275, hsa-mir-625, hsa-mir-452,
hsa-mir-628-3p, hsa-mir-30a*, and hsa-mir-30e*
CIAO1 Role in iron–sulfur
protein biogenesis
Interacts with tumor
suppressor WT1 (31)
Increased usage of
two proximal polyA
sites in the 3′ UTR
Shortening of 3′ UTR by up to 2581 nt with loss of miRNA target
sites for nine miRNAs present in SI-NETs: hsa-mir-550*,
hsa-mir-200c*, hsa-mir-214*, hsa-mir-423-5p, hsa-mir-660,
hsa-mir-29b-1*, hsa-mir-1246, hsa-mir-7-1*, and hsa-mir-7-2*
SRSF5 Splice factor Overexpressed in
breast cancer and
anti-apoptotic (32)
Increased usage of a
proximal polyA site
in the 3′ UTR
Shortening of 3′ UTR by 312 nt with loss of miRNA target sites for
seven miRNAs present in SI-NETs: hsa-mir-338-5p,
hsa-mir-628-3p, hsa-mir-409-3p, hsa-mir-183*, hsa-mir-330-3p,
hsa-mir-7-1*, and hsa-mir-7-2*
MRSP16 Mitochondrial
ribosomal protein
Unknown Increased usage of a
proximal polyA site
in the 3′ UTR
Shortening of 3′ UTR by 1888 nt with loss of miRNA target sites
for 16 miRNAs present in SI-NETs: hsa-mir-671-5p, hsa-mir-193b*,
hsa-mir-551b*, hsa-mir-338-5p, hsa-mir-30b*, hsa-mir-125b-2*,
hsa-mir-330-3p, hsa-mir-7-1*, hsa-mir-7-2*, hsa-mir-188-5p,
hsa-mir-769-5p, hsa-mir-324-3p, hsa-mir-552, hsa-mir-193a-5p,
hsa-mir-501-5p, and hsa-mir-362-5p
NDUFA6 NADH
dehydrogenase
Unknown Increased usage of a
proximal polyA site
in the 3′ UTR
Shortening of 3′ UTR by 563 nt with loss of miRNA target sites for
six miRNAs present in SI-NETs: hsa-mir-552, hsa-mir-21*,
hsa-mir-664*, hsa-mir-505*, hsa-mir-550, and hsa-mir-500*
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Table 4 | Genes with CR-APA specific to the SI-NETs.
Gene Function Role in cancer APA compared Functional consequence
DCC Receptor for the
axon guidance
molecule nextrin
Tumor suppressor (34) Increased usage of a
proximal polyA site
located in intron 5
Usage of this polyA site leads to expression of an mRNA
lacking 24 exons in the 3′ end, which translates into a highly
C-terminally truncated DCC protein containing only 5 Ig-like
domains and lacking both the nextrin binding domain, the
transmembrane domain, and the intracellular domain. Thus,
it lacks the parts responsible for the tumor suppressive
functions (34)
PDZD2 PDZ domain-
containing
protein
Can be cleaved near its
C-terminus to generate a
secreted form sPDZD2 with
tumor suppressive function
(35, 36)
Increased usage of
two proximal polyA
sites located in
intron 2
Usage of these polyA sites leads to expression of an mRNA
lacking 23 exons in the 3′ end, which translates a highly
C-terminally truncated PDZD2 protein, lacking the ability to
form sPDZD2 and thus the tumor suppressive function (35)
MAGI1 Scaffolding
protein localized
at cell–cell
contacts,
containing PDZ
domains
Tumor suppressive and
anti-metastatic, through
β-catenin recruitment to the
cell membrane and thus
inhibition of the Wnt/β-catenin
signaling pathway (37)
Increased usage of
two proximal intronic
polyA sites located
in the intron 2
Usage of these polyA sites leads to expression of an mRNA
lacking 21 exons in the 3′ end, which translates a highly
C-terminally truncated MAGI1 protein, lacking all PDZ
domains and thus the tumor suppressive function (37)
ZCWPW2 Zinc finger protein Unknown Increased usage of a
proximal polyA site
located in intron 5
Usage of this polyA site leads to expression of an mRNA
lacking five exons in the 3′ end, which translates into a
highly C-terminally truncated ZCWPW2 protein
LRRFIP1 Transcriptional
repressor
Overexpressed in cancer cell
lines (38) and pro-metastatic
(39)
Increased usage of a
proximal polyA site
located in the fifth
last intron
Usage of this polyA site leads to the expression of an
mRNA lacking five exons in the 3′ end. The 3′-end of this
mRNA isoform corresponds to the 3′-end of the 4.2-kB
mRNA overexpressed in cancer cell lines (38)
RIC3 Chaperone
protein
Unknown Increased usage of a
proximal intronic
polyA site located in
intron 1
Usage of this polyA site leads to the expression of an
mRNA lacking five exons in the 3′ end, giving rise to
C-terminally truncated RIC3 protein
THADA Unknown Frequently truncated in
thyroid adenomas and the
truncated allele is
hypothesized to play a role in
the thyroid tumorigenesis (40)
Increased usage of a
proximal polyA site
located in the
intron 22
Usage of this polyA site leads to the expression of an
mRNA lacking 16 exons in the 3′ end, i.e., more than in the
thyroid adenomas (40), which translates into highly
C-terminally truncated THADA protein
differential usage between the SI-NET group and PIT. The prox-
imal primer sets targeted intronic sequences, corresponding to 3′
UTRs of alternative last exons, and the distal primer sets targeted
either intronic sequences, corresponding to 3′ UTRs of alternative
last exons, or the 3′ UTRs of the last exon. As the proximal primer
sets targeted intronic sequences, the detection of a product from
these sets could only come from usage of the adjacent polyA site, as
the intron is otherwise spliced out. Proximal and distal isoforms
were thus individually measured. The genes were used as their
own controls, as there were two sets of primers for each gene; one
upstream of a proximal polyA site and one upstream of a distal
polyA site. The Ct values of the proximal and distal amplicon were
thus compared. Q-RT-PCR was run on triplicates of each sample
with all six primer sets. Median Ct values from the triplicates were
used for further analysis with individual Ct values deviating more
than two from the median considered as outliers and removed (2
of the 72 Ct values removed). In contrast to our results obtained
from DRS (Table 5), we found a higher expression of the proxi-
mal isoform of DCC and LRRFIP1, as well as a lower expression
of the proximal isoform of PDZD2 in all three SI-NETs as well
as in the reference sample (Table 6). However, when comparing
the results for the SI-NETs with our reference sample, we found
a higher expression of the proximal LRRFIP1 isoform in all three
SI-NETs compared to our reference sample. ForDCC and PDZD2,
we found a higher expression of the proximal isoform in two out
of the three SI-NETs compared to our reference sample (Table 7).
These Q-RT-PCR results validate the presence of the polyA sites
and the APA of these genes. They also indicate that these three
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Table 5 | Expression ratio of (short isoform/long isoform) derived from
DRS data.
DCC proximal/
distal
PDZD2 proximal/
distal
LRRFIP1 proximal/
distal
NE 2TC 25 14 3.725490196
NE CT1 156 15.66666667 2.173469388
NE MTT Inf 36 3.25
PIT 0.128205128 0.652631579 0.735294118
Table 6 | Expression ratio of (short isoform/long isoform) derived from
Q-RT-PCR data.
DCC proximal/
distal
PDZD2 proximal/
distal
LRRFIP1 proximal/
distal
NE 2TC 3.853506079 0.026305316 25.55396049
NE CT1 2.887782327 0.012957265 14.26667269
NE MTT 1.019851667 0.032658206 30.08928667
PIT 2.030313016 0.025800759 3.645085529
Table 7 | Expression ratio of (short isoform/long isoform) normalized
to reference sample, derived from Q-RT-PCR data.
DCC PDZD2 LRRFIP1
NE 2TC 1.897986 1.019556 7.010524
NE CT1 1.422334 0.502205 3.913947
NE MTT 0.502313 1.265785 8.254755
genes indeed undergo differential APA leading to the expression
of a larger amount of mRNAs with 3′ truncation of the coding
region in the SI-NETs than in the reference sample.
DISCUSSION
This is the first study to map polyA sites and characterize
APA genome-wide in SI-NETs. To map the polyA site usage
genome-wide we sequenced total RNA from three SI-NET samples
(NE MTT, NE CT1, and NE 2TC) and a reference sample (PIT)
using DRS (17). DRS is a well established method, which have been
used in several other studies to map polyA sites genome-wide (14,
17, 20, 21). Selected polyA sites have been confirmed in all cases
with PCR in three of those studies (14, 17, 21). We selected three
genes for Q-RT-PCR validation: DCC, PDZD2, and LRRFIP1. For
these three genes we validated the presence of all tested polyA sites
with Q-RT-PCR and thus the APA of the selected genes. However,
we did not find the same ratio of usage between the proximal and
distal polyA sites with Q-RT-PCR as we found with DRS (Tables 5
and 6). When comparing our Q-RT-PCR results in the SI-NETs
with the reference sample, they however indicate that the three
genes in the SI-NETs indeed undergo differential APA leading to
expression of a larger amount of mRNAs with 3′ truncation of the
coding region than in the reference sample (Table 7). The quanti-
tative differences found in expression ratios of the short and long
isoforms derived from DRS and Q-RT-PCR could be due to biases
and artifacts introduced during the synthesis of cDNA, contami-
nation of cDNA samples with genomic DNA and problems with
one or more of the primer sets.
When studying SI-NETs the optimal control sample would be
normal small intestinal neuroendocrine cells. These solitary cells,
which are interspersed among the other cells of the mucosa, are
however difficult to isolate (23). In one study, human neuroen-
docrine cells have been isolated by pronase/collagenase digestion,
gradient centrifugation, and FACS, but this method is complicated
and requires at least 5–8 cm of normal ileum (41). Additionally, it is
not certain if the RNA content is damaged during those processes.
Because of these difficulties, scrapings from the mucosa adjacent
to the tumors are normally used as reference samples. This mucosa
is however composed of a mix of various cell types, primarily ente-
rocytes and goblet cells. We believe that this mixture of cells from
the mucosa, despite a common origin with the neuroendocrine
cells (42), is phenotypically farther from intestinal neuroendocrine
cells than neuroendocrine cells elsewhere in the body. We therefore
chose to use pituitary as a reference sample as it mainly contains
neuroendocrine cells.
Using Fisher exact tests, we found 11031 polyA sites, located
in 97% of the expressed protein coding genes, with no statistical
difference in usage between the individual SI-NETs (FDR >0.1).
This shows similarity between the three SI-NET samples. Using the
same Fisher exact tests to compare APA in the SI-NETs and in the
reference sample, we identified 16 genes with significant APA spe-
cific to the SI-NETs, which lead to either 3′ truncation of mRNA
coding regions or 3′ UTRs (Figure S1 in Supplementary Material).
These 16 genes with APA specific to the SI-NETs could be tested
as diagnostic markers and drug targets for disease prevention and
treatment.
Nine of the 16 genes had significant UTR-APA in the SI-NETs
leading to 3′ UTR shortening in a larger proportion of mRNAs
than in the reference sample. Interestingly, four genes out of the
nine with UTR-APA have been found to be either overexpressed in
cancer: PSMD8 (27), CD59 (29), and SRSF5 (32) or is suggested
to be overexpressed: ANKH (30). The UTR-APA in these genes
produces mRNA isoforms that lack one or more target sites for
miRNAs present in SI-NETs. These mRNAs consequently escape
a part of the miRNA regulation and, therefore, should be more
stable and produce more protein (5, 11, 12). Thus, the changes
predicted in these nine genes suggest that UTR-APA could con-
tribute to the SI-NET tumorigenesis. One of these genes, DACT2,
was previously found as a tumor suppressor protein (28). The
UTR-APA in this gene leads to 3′ UTR shortening in a larger
proportion of mRNAs in the SI-NETs than in the reference sam-
ple. However, as no miRNA target sites are found in the short-
ened part of the 3′ UTR, it is unclear which role this 3′ UTR
region has. Apart from miRNAs, RNA binding proteins (RBPs)
also target the 3′ UTR of mRNAs and can affect the stability of
mRNAs (43). Thus, it is possible that the shortening of the 3′ UTR
affects the stability of DACT2 by removing putative binding sites
of RBPs.
Seven of the 16 genes had significant CR-APA in the SI-NETs
leading to 3′ truncated coding regions in a larger proportion of
mRNAs than in the reference sample. CR-APA alters the cod-
ing region of mRNAs and thus the isoform of the produced
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protein. Remarkably, three out of the seven genes with CR-APA
have tumor suppressive functions: DCC (34), PDZD2 (35), and
MAGI1 (37). The CR-APA in these genes produces mRNA iso-
forms lacking several 3′-terminal exons, translating into highly
C-terminally truncated proteins. These protein isoforms lack the
parts responsible for the tumor suppressive functions. The CR-
APA inDCC,PDZD2, andMAGI1 could thus likely be contributing
to the tumorigenesis in SI-NETs. DCC is located in chromosome
18, where there have been reported frequent copy-number losses
in SI-NETs (44, 45). The copy-number losses might truncate the
DCC gene, forcing the usage of the proximal polyA site. Another
gene with CR-APA, THADA, has been hypothesized to contribute
to the tumorigenesis of thyroid adenomas in its truncated form
(40). The CR-APA found in the SI-NETs produces an mRNA even
more 3′-terminally truncated and could thus also be a candidate
contributing to the tumorigenesis of SI-NETs. One gene stands
out in the CR-APA group, LRRFIP1, as it has been shown to be
overexpressed in cancer cell lines (38) and to be pro-metastatic
(39). The CR-APA of this gene in the SI-NETs gives rise to an
mRNA isoform, with a 3′-end corresponding to the 3′-end of the
4.2 kB mRNA overexpressed in cancer cell lines (38). CR-APA of
LRRFIP1 could thus also be a contributor to the tumorigenesis in
SI-NETs, as the major mRNA isoform expressed in the SI-NETs is
likely equal to that overexpressed in the cancer cell lines.
The suggested participation of APA in the tumorigenesis of
SI-NETs could lead to new medical treatments of SI-NETs. This
is particularly interesting as polyA sites of interest can be very
specifically and effectively blocked and patterns of APA can thus
be changed. Different techniques utilizing antisense elements have
already been used to effectively inhibit polyA site usage. They
include antisense oligonucleotides (46), siRNAs (47),and U1 mod-
ifications (48–52). Such techniques could, e.g., be used to force
the expression of the full-length mRNAs of the tumor suppressor
genes DCC, PDZD2, and MAGI1.
As this study was performed on only three SI-NET samples the
findings should be confirmed in a larger cohort. Preferably, future
studies on APA in SI-NETs should also include alternative reference
tissues and use different methods for characterizing poly(A) site
usage. The findings could also be tested in other types of NETs. If
the findings are confirmed, the effects of blocking the implicated
proximal poly(A) sites with antisense elements should be tested
experimentally.
In conclusion, we have mapped for the first time polyA sites
genome-wide in SI-NETs. We found 11031 polyA sites, located
in 97% of the expressed protein coding genes, with no statistical
difference in usage between the individual SI-NETs. This shows
similarity between the three SI-NET samples. In the SI-NETs, we
identified 16 genes with significant APA leading to either 3′ trun-
cation of coding regions or 3′ UTRs in a larger proportion of
mRNAs than in the reference sample (Tables 3 and 4). The APA
was confirmed in three genes using Q-RT-PCR:DCC,PDZD2, and
LRRFIP1. However, we did not find the same expression ratios
between the proximal and distal isoforms for these genes with
Q-RT-PCR as with DRS (Tables 5 and 6).
As 11 of the 16 identified genes have previously been associated
with cancer, it is likely that APA in these genes could take part
in the SI-NET tumorigenesis. Future studies will have to confirm
these findings in a larger cohort. The identified 16 genes with APA
specific to the SI-NETs could be tested as diagnostic markers and
as drug targets for disease prevention and treatment.
AUTHOR CONTRIBUTIONS
Study concept and design (Anders Rehfeld, Lennart Friis-Hansen).
Acquisition of data (Anders Rehfeld, Lennart Friis-Hansen).
Analysis and interpretation of data (Anders Rehfeld, Mireya Plass,
Anders Krogh, Lennart Friis-Hansen). Drafting of the manuscript
(Anders Rehfeld, Mireya Plass, Lennart Friis-Hansen). Critical
revision of the manuscript for important intellectual content
(Anders Rehfeld, Mireya Plass, Kristina Døssing, Ulrich Knigge,
Andreas Kjær, Anders Krogh, Lennart Friis-Hansen). Statisti-
cal analysis (Mireya Plass, Anders Krogh). Obtained funding
(Anders Rehfeld, Anders Krogh, Lennart Friis-Hansen). Admin-
istrative, technical, or material support (Lennart Friis-Hansen).
Study supervision (Lennart Friis-Hansen).
ACKNOWLEDGMENTS
The work in laboratories of the authors was supported by the
Danish MRC, Rigshospitalet. Funding: this work was supported by,
The Danish Council for Independent Research – Medical Sciences,
The Danish Council for Strategic Research, The Novo Nordisk
Foundation, and Rigshospitalet.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Journal/10.3389/fendo.2014.00046/
abstract
REFERENCES
1. Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-
pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol (2012) 23(Suppl 7):vii124–30. doi:10.1093/annonc/
mds295
2. Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, et al. Nordic
guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroen-
docrine tumours. Acta Oncol (2010) 49:740–56. doi:10.3109/0284186X.2010.
492791
3. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemi-
ology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin
North Am (2011) 40:1–18. doi:10.1016/j.ecl.2010.12.005
4. Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM. The diversity and
commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks
Arch Surg (2011) 396:273–98. doi:10.1007/s00423-011-0739-1
5. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. Proliferating cells express
mRNAs with shortened 3’untranslated regions and fewer microRNA target sites.
Science (2008) 320:1643–7. doi:10.1126/science.1155390
6. Ji Z, Tian B. Reprogramming of 3’ untranslated regions of mRNAs by alternative
polyadenylation in generation of pluripotent stem cells from different cell types.
PLoS One (2009) 4:e8419. doi:10.1371/journal.pone.0008419
7. Derti A, Garrett-Engele P, Macisaac KD, Stevens RC, Sriram S, Chen R, et al.
A quantitative atlas of polyadenylation in five mammals. Genome Res (2012)
22:1173–83. doi:10.1101/gr.132563.111
8. Danckwardt S, Hentze MW, Kulozik AE. 3’ End mRNA processing: molecular
mechanisms and implications for health and disease.EMBO J (2008) 27:482–98.
doi:10.1038/sj.emboj.7601932
9. Rehfeld A, Plass M, Krogh A, Friis-Hansen L. Alterations in polyadenylation and
its implications for endocrine disease. Front Endocrinol (Lausanne) (2013) 4:53.
doi:10.3389/fendo.2013.00053
Frontiers in Endocrinology | Cancer Endocrinology April 2014 | Volume 5 | Article 46 | 8
Rehfeld et al. Alternative polyadenylation in SI-NETs
10. Elkon R, Drost J, van Haaften G, Jenal M, Schrier M, Vrielink JAO, et al. E2F
mediates enhanced alternative polyadenylation in proliferation. Genome Biol
(2012) 13:R59. doi:10.1186/gb-2012-13-7-r59
11. Singh P, Alley TL, Wright SM, Kamdar S, Schott W, Wilpan RY, et al. Global
changes in processing of mRNA 3’ untranslated regions characterize clinically
distinct cancer subtypes.CancerRes (2009) 69:9422–30. doi:10.1158/0008-5472.
CAN-09-2236
12. Mayr C, Bartel DP. Widespread shortening of 3’UTRs by alternative cleavage
and polyadenylation activates oncogenes in cancer cells.Cell (2009) 138:673–84.
doi:10.1016/j.cell.2009.06.016
13. Morris AR, Bos A, Diosdado B, Rooijers K, Elkon R, Bolijn AS, et al. Alterna-
tive cleavage and polyadenylation during colorectal cancer development. Clin
Cancer Res (2012) 18:5256–66. doi:10.1158/1078-0432.CCR-12-0543
14. Lin Y, Li Z, Ozsolak F, Kim SW, Arango-Argoty G, Liu TT, et al. An in-depth
map of polyadenylation sites in cancer. Nucleic Acids Res (2012) 40:8460–71.
doi:10.1093/nar/gks637
15. Fu Y, Sun Y, Li Y, Li J, Rao X, Chen C, et al. Differential genome-wide pro-
filing of tandem 3’ UTRs among human breast cancer and normal cells by
high-throughput sequencing. Genome Res (2011) 21:741–7. doi:10.1101/gr.
115295.110
16. Lembo A, Di Cunto F, Provero P. Shortening of 3’UTRs correlates with poor
prognosis in breast and lung cancer. PLoS One (2012) 7:e31129. doi:10.1371/
journal.pone.0031129
17. Ozsolak F, Platt AR, Jones DR, Reifenberger JG, Sass LE, McInerney P, et al.
Direct RNA sequencing. Nature (2009) 461:814–8. doi:10.1038/nature08390
18. Tian B, Hu J, Zhang H, Lutz CS. A large-scale analysis of mRNA polyadeny-
lation of human and mouse genes. Nucleic Acids Res (2005) 33:201–12.
doi:10.1093/nar/gki158
19. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, et al. Ensembl 2013.
Nucleic Acids Res (2013) 41:D48–55. doi:10.1093/nar/gks1236
20. Ozsolak F, Kapranov P, Foissac S, Kim SW, Fishilevich E, Monaghan AP, et al.
Comprehensive polyadenylation site maps in yeast and human reveal pervasive
alternative polyadenylation. Cell (2010) 143:1018–29. doi:10.1016/j.cell.2010.
11.020
21. Sherstnev A, Duc C, Cole C, Zacharaki V, Hornyik C, Ozsolak F, et al.
Direct sequencing of Arabidopsis thaliana RNA reveals patterns of cleavage
and polyadenylation. Nat Struct Mol Biol (2012) 19:845–52. doi:10.1038/nsmb.
2345
22. Ahlman H, Nilsson O. The gut as the largest endocrine organ in the body. Ann
Oncol (2001) 12(Suppl 2):S63–8. doi:10.1093/annonc/12.suppl_2.S63
23. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Tötterman TH, et al. Novel
markers for enterochromaffin cells and gastrointestinal neuroendocrine carci-
nomas. Mod Pathol (2009) 22:261–72. doi:10.1038/modpathol.2008.174
24. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are
conserved targets of microRNAs. Genome Res (2009) 19:92–105. doi:10.1101/
gr.082701.108
25. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource:
targets and expression. Nucleic Acids Res (2008) 36:D149–53. doi:10.1093/nar/
gkm995
26. Li S-C, Essaghir A, Martijn C, Lloyd RV, Demoulin J-B, Oberg K, et al. Global
microRNA profiling of well-differentiated small intestinal neuroendocrine
tumors. Mod Pathol (2013) 26(5):685–96. doi:10.1038/modpathol.2012.216
27. Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T, et al. Over-expression of genes
and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits
(PSs) in breast cancer tissue observed by the methods of RFDD-PCR and
proteomics.Breast Cancer ResTreat (2007) 104:21–30. doi:10.1007/s10549-006-
9393-7
28. Hou J, Liao L-D, Xie Y-M, Zeng F-M, Ji X, Chen B, et al. DACT2 is a can-
didate tumor suppressor and prognostic marker in esophageal squamous cell
carcinoma. Cancer Prev Res (Phila) (2013) 6:791–800. doi:10.1158/1940-6207.
CAPR-12-0352
29. Li B, Lin H, Fan J, Lan J, Zhong Y, Yang Y, et al. CD59 is overexpressed in human
lung cancer and regulates apoptosis of human lung cancer cells. Int J Oncol
(2013) 43:850–8. doi:10.3892/ijo.2013.2007
30. Kloth JN, Oosting J, van Wezel T, Szuhai K, Knijnenburg J, Gorter
A, et al. Combined array-comparative genomic hybridization and single-
nucleotide polymorphism-loss of heterozygosity analysis reveals complex
genetic alterations in cervical cancer. BMC Genomics (2007) 8:53. doi:10.1186/
1471-2164-8-53
31. Johnstone RW, Wang J, Tommerup N, Vissing H, Roberts T, Shi Y. Ciao 1 is
a novel WD40 protein that interacts with the tumor suppressor protein WT1.
J Biol Chem (1998) 273:10880–7. doi:10.1074/jbc.273.18.10880
32. Gautrey HL, Tyson-Capper AJ. Regulation of Mcl-1 by SRSF1 and
SRSF5 in cancer cells. PLoS One (2012) 7:e51497. doi:10.1371/journal.pone.
0051497
33. Lejeune F, Maquat LE. Mechanistic links between nonsense-mediated mRNA
decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol (2005)
17:309–15. doi:10.1016/j.ceb.2005.03.002
34. Duman-Scheel M. Deleted in colorectal cancer (DCC) pathfinding: axon guid-
ance gene finally turned tumor suppressor.CurrDrugTargets (2012) 13:1445–53.
doi:10.2174/138945012803530215
35. Tam CW, Liu VWS, Leung WY, Yao K-M, Shiu SYW. The autocrine human
secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or
quiescence of prostate, breast and liver cancer cells via transcriptional activation
of p53. Cancer Lett (2008) 271:64–80. doi:10.1016/j.canlet.2008.05.047
36. Yeung M-L, Tam TSM, Tsang ACC, Yao K-M. Proteolytic cleavage of PDZD2
generates a secreted peptide containing two PDZ domains. EMBO Rep (2003)
4:412–8. doi:10.1038/sj.embor.embor804
37. Zaric J, Joseph J-M, Tercier S, Sengstag T, Ponsonnet L, Delorenzi M, et al. Identi-
fication of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2
inhibitors in colorectal cancer cells. Oncogene (2012) 31:48–59. doi:10.1038/
onc.2011.218
38. Rikiyama T, Curtis J, Oikawa M, Zimonjic DB, Popescu N, Murphy BA, et al.
GCF2: expression and molecular analysis of repression. Biochim Biophys Acta
(2003) 1629:15–25. doi:10.1016/S0167-4781(03)00156-8
39. Ariake K, Ohtsuka H, Motoi F, Douchi D, Oikawa M, Rikiyama T, et al.
GCF2/LRRFIP1 promotes colorectal cancer metastasis and liver invasion
through integrin-dependent RhoA activation. Cancer Lett (2012) 325:99–107.
doi:10.1016/j.canlet.2012.06.012
40. Rippe V, Drieschner N, Meiboom M, Murua Escobar H, Bonk U, Belge G, et al.
Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas.
Oncogene (2003) 22:6111–4. doi:10.1038/sj.onc.1206867
41. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC. The functional
characterization of normal and neoplastic human enterochromaffin cells. J Clin
Endocrinol Metab (2006) 91:2340–8. doi:10.1210/jc.2006-0110
42. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al.
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 9:61–72.
doi:10.1016/S1470-2045(07)70410-2
43. Keene JD. RNA regulons: coordination of post-transcriptional events. Nat Rev
Genet (2007) 8:533–43. doi:10.1038/nrg2111
44. Hashemi J, Fotouhi O, Sulaiman L, Kjellman M, Höög A, Zedenius J, et al.
Copy number alterations in small intestinal neuroendocrine tumors deter-
mined by array comparative genomic hybridization.BMCCancer (2013) 13:505.
doi:10.1186/1471-2407-13-505
45. Andersson E, Swärd C, Stenman G, Ahlman H, Nilsson O. High-resolution
genomic profiling reveals gain of chromosome 14 as a predictor of poor out-
come in ileal carcinoids. Endocr Relat Cancer (2009) 16:953–66. doi:10.1677/
ERC-09-0052
46. Vorlová S, Rocco G, Lefave CV, Jodelka FM, Hess K, Hastings ML, et al. Induc-
tion of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA
activation. Mol Cell (2011) 43:927–39. doi:10.1016/j.molcel.2011.08.009
47. Vickers TA, Crooke ST. siRNAs targeted to certain polyadenylation sites promote
specific, RISC-independent degradation of messenger RNAs. Nucleic Acids Res
(2012) 40:6223–34. doi:10.1093/nar/gks239
48. Fortes P, Cuevas Y, Guan F, Liu P, Pentlicky S, Jung SP, et al. Inhibiting expres-
sion of specific genes in mammalian cells with 5’ end-mutated U1 small nuclear
RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A (2003)
100:8264–9. doi:10.1073/pnas.1332669100
49. Beckley SA, Liu P, Stover ML, Gunderson SI, Lichtler AC, Rowe DW. Reduc-
tion of target gene expression by a modified U1 snRNA. Mol Cell Biol (2001)
21:2815–25. doi:10.1128/MCB.21.8.2815-2825.2001
50. Blazquez L, Gonzalez-Rojas SJ, Abad A, Razquin N, Abad X, Fortes P. Increased
in vivo inhibition of gene expression by combining RNA interference and U1
inhibition. Nucleic Acids Res (2012) 40:e8. doi:10.1093/nar/gkr956
www.frontiersin.org April 2014 | Volume 5 | Article 46 | 9
Rehfeld et al. Alternative polyadenylation in SI-NETs
51. Goraczniak R, Behlke MA, Gunderson SI. Gene silencing by synthetic U1 adap-
tors. Nat Biotechnol (2009) 27:257–63. doi:10.1038/nbt.1525
52. Vickers TA, Sabripour M, Crooke ST. U1 adaptors result in reduction of multi-
ple pre-mRNA species principally by sequestering U1snRNP. Nucleic Acids Res
(2011) 39:e71. doi:10.1093/nar/gkr150
53. Di Giammartino DC, Nishida K, Manley JL. Mechanisms and consequences
of alternative polyadenylation.Mol Cell (2011) 43:853–66. doi:10.1016/j.molcel.
2011.08.017
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 09 February 2014; accepted: 22 March 2014; published online: 15 April 2014.
Citation: Rehfeld A, Plass M, Døssing K, Knigge U, Kjær A, Krogh A and Friis-Hansen
L (2014) Alternative polyadenylation of tumor suppressor genes in small intestinal
neuroendocrine tumors. Front. Endocrinol. 5:46. doi: 10.3389/fendo.2014.00046
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers
in Endocrinology.
Copyright © 2014 Rehfeld, Plass, Døssing , Knigge, Kjær, Krogh and Friis-Hansen.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | Cancer Endocrinology April 2014 | Volume 5 | Article 46 | 10
